Pharma & Biotech Global Week in Review 2 May 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

11th Circuit rules against the FTC in Androgel patent settlement appeal; Sen. Bingaman pushes for legislative remedy (FDA Law Blog) (Patent Docs)

CAFC sets briefing deadline, oral argument date for Myriad isolated DNA case (Pharma Patents) (Patent Docs) (Patently-O)

Synriam (Arterolane, Piperquine) – India: The story behind Ranbaxy’s new drug (Spicy IP) (Spicy IP) (Spicy IP)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Confidential documents show tough staff choices at Global Fund to Fight AIDS, TB and Malaria (IP Watch)

Denmark: A new decision on second medical use – Vericore Limited vs. The Danish Board of Appeals (Kluwer Patent Blog)

EU: Enlarged Board of Appeal to consider breeding processes again (Patent Docs)

EU: The FORUM February seminar on SPCs: a report (The SPC Blog)

India/US: USTR 301 Report surprisingly restrained on Bayer compulsory license decision (Spicy IP)

Kenyan Court holds Anti-Counterfeit Act unconstitutional (Spicy IP)

US: Senate HELP Committee proposes evaluation of Innovation Inducement Prizes, as alternative to product monopolies (KEI)

US: National Bioeconomy Blueprint 2012 (Patent Baristas)

US: Congressional Hearing on international patent issues: BIO submits comments (BIOtechNOW)

US: BIO comments on FDA biosimilars guidance: demand more testing, permit fewer differences (Patent Docs)

US: CAFC sets briefing deadline, oral argument date for Myriad isolated DNA case (Pharma Patents) (Patent Docs) (Patently-O)

US: Vlog: why Prometheus doesn’t govern Myriad but might impact it anyway (Pharma Patents)

US: Book discussion: Frischmann predicts Prometheus (Patently-O)

 

Products

Abilify (Aripiprazole) – Australia: Full Federal Court to hear appeal against generic drug injunction: Generic Health v Otsuka (IP Whiteboard)

Alimta (Pemetrexed) – US: Eli Lilly files patent infringement suit against Apotex in response to Para IV challenge (Patent Docs)

Androgel (Testosterone gel) – US: 11th Circuit rules against the FTC in Androgel patent settlement appeal; Sen. Bingaman pushes for legislative remedy (FDA Law Blog) (Patent Docs)

Caduet (Atorvastatin, Amlodipine) – US: Pfizer files patent infringement suit against Dr Reddy’s in response to Para IV challenge (Patent Docs)

Coenzyme Q10 – US: ALJ Rogers grants-in-part motion to compel in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog)

Combigan (Brimonidine tartrate, Timolol maleate) – US: Allergan files patent infringement suit against Sandoz in reponse to ANDA filing (Patent Docs)

Glumetza (Metformin) – US: Depomed files patent infringement suit against Watson in response to Para IV challenge (Patent Docs)

Gralise (Gabapentin) – US: Depomed files patent infringement suit against Impax in response to Para IV challenge (Patent Docs)

Metadate CD (Methylphenidate) – US: UCB files patent infringement suit against Mallinckrodt in response to Para IV challenge (Patent Docs)

Norvir (Ritonavir) – US: Abbott files patent infringement conplaint against Roxane in response to Para IV challenge; Roxane files for declaratory judgment of invalidity and noninfringement (Patent Docs)

OxyContin (Oxycodone) – US: Purdue Pharma files patent infringement suit against Mylan in response to Para IV challenge (Patent Docs)

OxyContin (Oxycodone) – US: Purdue Pharma files patent infringement complaints in ED Pennsylvania and SD New York against Varam following Para IV certification (Patent Docs)

Seroquel (Quetiapine) – US: Astrazeneca files patent infringement suit against Intellipharmaceuticals in response to Para IV challenge (Patent Docs)

Synriam (Arterolane, Piperquine) – India: The story behind Ranbaxy’s new drug (Spicy IP) (Spicy IP) (Spicy IP)

Tarceva (Erlotinib) –US: OSI Pharmaceuticals files patent infringement suit against Roxane in response to Para IV challenge (Patent Docs)

Vancocin (Vancomycin) – US: Court denies ViroPharma’s motion for TRO/PI in Vancomycin case—leaves generics on the market (FDA Law Blog)

Yasmin (Drospirenone, Ethinyl estradiol) – US: CAFC clears the way for generic Yasmin: Bayer Schering Pharma v Lupin (Pharma Patents)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: